Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 16/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 11/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28267155 | 0.78 | MTOR (0.43) | PIK3CAMTOR | |
| SCHEMBL8216315 | 0.78 | NSD2 (0.34) | PIK3CAATRATRIPMTOR | |
| SCHEMBL8216310 | 0.78 | NSD2 (0.34) | PIK3CAATRATRIPMTOR | |
| SCHEMBL28539901 | 0.76 | ATR (0.55) | PIK3CDPIK3CAATRATRIPPDE4D | |
| SCHEMBL28539899 | 0.76 | ATR (0.55) | PIK3CDPIK3CAATRATRIPPDE4D | |
| SCHEMBL2127456 | 0.76 | ATR (0.55) | PIK3CDPIK3CAATRATRIPPDE4D | |
| SCHEMBL29442179 | 0.76 | ATR (0.55) | PIK3CDPIK3CAATRATRIPPDE4D | |
| SCHEMBL29947221 | 0.75 | PIK3CA (0.50) | PIK3CDPIK3CAATRATRIPPDE4D | |
| SCHEMBL28958536 | 0.75 | PIK3CA (0.50) | PIK3CDPIK3CAATRATRIPPDE4D | |
| SCHEMBL15141832 | 0.73 | ATR (0.46) | PIK3CDPIK3CAATRATRIPCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | PIK3CD 233/4885PIK3CA 664/4885ATR 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.